As shown in Figure 9C, compared to the high-risk group, CRC patients in the low-risk group express higher levels of immunotherapeutic biomarkers, including PD-1, PD-L1, TIM-3, and CTLA-4. This evidence concerns the gene HAVCR2 and colorectal carcinoma.